Research shows the Multiple Sclerosis Flowsheet database has demonstrated acceptability among staff and clinicians.
The investigators of this Phase 3 study sought to evaluate the efficacy and safety of ADS-5102 (amantadine) extended-release capsules to treat multiple sclerosis patients with walking impairment.
Interactive discussions with healthcare practitioners (HCPs) and patient education regarding multiple sclerosis (MS) relapse increases the likelihood of patients reporting relapses and achieving more proactive disease management
Study evaluates the benefits of ocrelizumab on 48-week confirmed disability progression in MS observed in pooled OPERA I and OPERA II, as well as a 3 year ocrelizumab treatment in an open-label extension.
Study demonstrated efficacy in improving communication with the clinician, lowering the number of visits, and improving the coordination of single-day multi-service and therapeutic interventions in multiple sclerosis
The clinician workgroup achieved a consensus and report a 3-step iterative management algorithm for MS relapses.
Investigators sought to determine the safety and efficacy of twice-daily dosing of arbaclofen ER in patients with spasticity due to multiple sclerosis.
Individuals with multiple sclerosis undergoing dimethyl fumarate therapy may be vulnerable to herpes simplex encephalitis.
Despite the occurrence of thyroid adverse events or their severity, AEs had a minimal impact on quality of life for patients with relapsing-remitting multiple sclerosis who had been treated with alemtuzumab.
Investigators hypothesize siponimod will function as an alternative therapeutic choice to monoclonal antibodies in MS.
Investigators examine the use treatment patterns and utilization of disease-modifying therapy in newly diagnosed pediatric patients with multiple sclerosis.
Investigators sought to determine the 8-year safety and efficacy of alemtuzumab in patients with relapsing-remitting multiple sclerosis from the CARE-MS I and II studies.
Patients with multiple sclerosis with a lapse of >60 days of therapy may result in more lapses, resource use, and higher cost.
Age- and sex-stratified comorbidity and concomitant medication use has been found among individuals with MS who have newly initiated disease-modifying drugs.
The investigators of this study sought to evaluate the long-term efficacy and safety of alemtuzumab to treat patients of African descent who have relapsing-remitting MS.